Full Press Release Details
Announces Correction to its Reported Unaudited Loss
Per Share from ($0.06) to ($0.04) for the Quarter Ended December 31, 2019
PORTLAND, Maine - February 19, 2020 -
ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company
that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of
dairy and beef cattle, today announced a correction to its unaudited loss per share calculation for the fourth quarter ended
The unaudited weighted average shares outstanding was incorrectly
reported as 5,408,000 resulting in a loss per share calculation of ($0.06). The corrected unaudited weighted average shares outstanding
is 7,210,000 resulting in a loss per share calculation of ($0.04).
Interested parties can access a replay of the February 19, 2020 teleconference held by the Company by dialing (877) 344-7529
(toll free) or (412) 317-0088 (international), utilizing confirmation #10138781 until February 26, 2020. Investors are encouraged
to review the Company's updated Corporate Presentation slide deck that provides an overview of the Company's business
and is available under the "Investors" tab of the Company's website at www.immucell.com, or by request to the
Company. The Company expects to file its Annual Report on Form 10-K on or about March 27, 2020.
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically-proven and practical products that improve
the health and productivity of dairy and beef cattle. ImmuCell markets First Defense , providing Immediate
Immunity to newborn dairy and beef livestock, and is in the late stages of developing Re-Tain , a novel
treatment for subclinical mastitis without a milk discard requirement that provides an alternative to traditional antibiotics.
Press releases and other information about the Company are available at: http://www.immucell.com.
Joe Diaz, Robert Blum and Joe Dorame
Lytham Partners, LLC